The challenge of diagnosing and treating bladder câncer
DOI:
https://doi.org/10.33448/rsd-v11i5.28252Keywords:
Urinary Bladder Neoplasms; Urinary bladder; Urinary Bladder Diseases; Cystostomy.Abstract
Introduction: Bladder cancer is the ninth most common neoplasm worldwide. It is a diverse disease with different outcomes related to its underlying basic biology, responsiveness to therapy, and host-related factors. Established risk factors for bladder cancer include male gender, older age, white race, occupational exposure to certain chemicals, pelvic radiation, use of medications such as cyclophosphamide, chronic bladder infection/irritation, personal or family history of bladder cancer, and smoking. Method: The search platform on the following sites: SciELO, Google academic, International Brazilian Journal of Urology, The Journal of Urology, PUBLAB and PUBMED. Outcome and Discussion: As a result, the spectrum of disease ranges from a relatively benign entity that is more troublesome than anything else to a lethal variant with great metastatic potential. For these reasons, early detection, markers of disease progression, and good surgical and medical therapies are paramount to impacting its natural history. Over the past 30 years, advances in endoscopic and surgical technique, along with discoveries in immunotherapy and chemotherapy, have resulted in substantial improvements in the care of patients with this disease. Conclusion: In this literature review, we highlight recent findings that establish a new and emerging standard of care for the treatment and diagnosis of patients with bladder cancer. As bladder cancer recurrence and mortality rates are high, research is needed to find suitable biomarkers for early detection, assessment of prognosis, and surveillance of drug responses.
References
Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., & Bray, F. (2017). Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. European Urology, 71(1), 96–108.
Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., & Bray, F. (2017). Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. European Urology, 71(1), 96–108.
Bochenek, K., Aebisher, D., Międzybrodzka, A., Cieślar, G., & Kawczyk-Krupka, A. (2019). Methods for bladder cancer diagnosis – The role of autofluorescence and photodynamic diagnosis. Photodiagnosis and Photodynamic Therapy, 27, 141–148.
Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B., & Hauser, R. (2003). The health economics of bladder cancer. PharmacoEconomics, 21(18), 1315–1330.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424.
Charlton, M. E., Adamo, M. P., Sun, L., & Deorah, S. (2014). Bladder cancer collaborative stage variables and their data quality, usage, and clinical implications: A review of SEER data, 2004-2010. Cancer, 120, 3815–3825.
Drost, J., & Clevers, H. (2017). Translational applications of adult stem cell-derived organoids. Development, 144(6), 968–975.
Farling, K. B. (2017). Bladder cancer. The Nurse Practitioner, 42(3), 26–33.
Ferrucci, L. M., Sinha, R., Ward, M. H., Graubard, B. I., Hollenbeck, A. R., Kilfoy, B. A., Schatzkin, A., Michaud, D. S., & Cross, A. J. (2010). Meat and components of meat and the risk of bladder cancer in the NIH-AARP Diet and Health Study. Cancer, 116(18), 4345–4353.
Freedman, N. D. (2011). Association Between Smoking and Risk of Bladder Cancer Among Men and Women. JAMA, 306(7), 737.
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians, 61(2), 69–90.
Key Statistics for Bladder Cancer. (n.d.). Www.cancer.org. 2022.
Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E., & Ulbright, T. M. (2016). The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. European Urology, 70(1), 93–105.
Mullenders, J., Jongh, E. de, Brousali, A., Roosen, M., Blom, J. P. A., Begthel, H., Korving, J., Jonges, T., Kranenburg, O., Meijer, R., & Clevers, H. C. (2019). Mouse and human urothelial cancer organoids: A tool for bladder cancer research. Proceedings of the National Academy of Sciences, 116(10), 4567–4574.
Robertson, A. G., Kim, J., Al-Ahmadie, H., Bellmunt, J., Guo, G., Cherniack, A. D., Hinoue, T., Laird, P. W., Hoadley, K. A., Akbani, R., Castro, M. A. A., Gibb, E. A., Kanchi, R. S., Gordenin, D. A., Shukla, S. A., Sanchez-Vega, F., Hansel, D. E., Czerniak, B. A., Reuter, V. E., & Su, X. (2017). Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell, 171(3), 540-556.e25.
Royce, T. J., Feldman, A. S., Mossanen, M., Yang, J. C., Shipley, W. U., Pandharipande, P. V., & Efstathiou, J. A. (2019). Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 17(1), 23-31.e3.
Sanli, O., Dobruch, J., Knowles, M. A., Burger, M., Alemozaffar, M., Nielsen, M. E., & Lotan, Y. (2017). Bladder cancer. Nature Reviews Disease Primers, 3(1), 1–19.
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71(1), 7–33.
Teoh, J. Y.-C., Huang, J., Ko, W. Y.-K., Lok, V., Choi, P., Ng, C.-F., Sengupta, S., Mostafid, H., Kamat, A. M., Black, P. C., Shariat, S., Babjuk, M., & Wong, M. C.-S. (2020). Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. European Urology, 78(6), 893–906.
Werntz, R. P., Adamic, B., & Steinberg, G. D. (2018). Emerging therapies in the management of high-risk non-muscle invasive bladder cancer (HRNMIBC). World Journal of Urology, 37(10), 2031–2040.
Wong, M. C. S., Fung, F. D. H., Leung, C., Cheung, W. W. L., Goggins, W. B., & Ng, C. F. (2018). The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Scientific Reports, 8(1).
Yin, M., Joshi, M., Meijer, R. P., Glantz, M., Holder, S., Harvey, H. A., Kaag, M., Fransen van de Putte, E. E., Horenblas, S., & Drabick, J. J. (2016). Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. The Oncologist, 21(6), 708–715.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 João Victor Carvalho da Paz; Vinícius Santos Mendes Restier; Igor Penha Paz ; Luís Carlos Machado e Silva; Camila Melo de Freitas; Beatriz de Sá Mota; João Batista Rebouças Lima; Lucas Frota Beckman; Giorge Júlio Dantas Martins ; Carleany Almeida dos Santos ; Elayne Paula de Oliveira Holanda; Leonildes Carvalho Godinho Segundo; Dyego Mondego Moraes; Carlos Matheus Teixeira Oliveira; Alexandre Augusto Gomes Alves
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
